Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02497287 · ClinicalTrials.gov registry record · Phase 3
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 802
- Enrollment target
NCT02497287 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 802 participants.
The verdict
NCT02497287, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 802 participants
- Enrollment target
Study Summary
The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).
Interventions
- DRUG Duloxetine (Oral Antidepressant)
- DRUG Escitalopram (Oral Antidepressant)
- DRUG Sertraline (Oral Antidepressant)
- DRUG Esketamine (Intranasal Spray)
- DRUG Venlafaxine Extended Release (XR) (Oral Antidepressant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 802 participants |
| Start Date | 2015-09-30 |
| Est. Completion | 2017-10-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02497287
The ClinicalTrials.gov registry entry for NCT02497287 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 802 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Duloxetine (Oral Antidepressant) is the first listed.
NCT02497287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02497287 about?
NCT02497287 is a clinical study titled "A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression". The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).
What is the current status of trial NCT02497287?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 802 participants. The study started on 2015-09-30. Estimated completion is 2017-10-28.
What interventions are being tested in trial NCT02497287?
The interventions under investigation include: Duloxetine (Oral Antidepressant) (DRUG), Escitalopram (Oral Antidepressant) (DRUG), Sertraline (Oral Antidepressant) (DRUG), Esketamine (Intranasal Spray) (DRUG), Venlafaxine Extended Release (XR) (Oral Antidepressant) (DRUG).
Who is sponsoring clinical trial NCT02497287?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.